The efficacy of Mizoribine for scleroderma of systemic sclerosis.

The efficacy of Mizoribine for scleroderma of systemic sclerosis. - The efficacy of Mizoribine for scleroderma of systemic sclerosis.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004162

Enrollment

Registered

2010-09-05

Start date

2010-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

systemic sclerosis

Interventions

a group of Mizoribine a group of the existing treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The cases of severe systemic screlosis and intractable skin screlosis by the existing treatment.

Exclusion criteria

Exclusion criteria: The cases of hypersensitivity for Mizoribine.

Design outcomes

Primary

Measure	Time frame
skin screlosis	—

Countries

Japan

Contacts

Public ContactTakamitsu Makino

Faculty of Life Sciences, Kumamoto University Department of Dermatology and Plastic Surgery

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026